The objective is the recruitment of talent with deep learning and biochemistry knowledge in Taiwan
Top Prizes include a 15" MacBook Pro and high-end GPUs
The top three Taiwan participants have the opportunity to join Insilico Taiwan's R&D team
TAIPEI, TAIWAN - Media OutReach
- February 25, 2019 - Insilco Medicine, one of the world's leading artificial
intelligence (AI) companies in the field of deep learning for drug discovery,
will host MolHack 2019 in Taiwan, an online talent competition/hackathon from
February 25th to March 31st. With a
focus of "Deep Learning for Small Molecule Generation," the event is expected
to attract top teams in deep learning and biochemistry from around the world to
participate. The top prize is a 15" MacBook Pro, with second and third prizes
of high-end NVIDIA GPUs. Additionally,
the top 3 entrants in Taiwan will have the opportunity to join Insilico
Medicine as a member of its R&D team.
MolHack 2019: Deep Learning Hackathon for Drug
discovery efforts take years or even decades to develop new pharmaceuticals.
Insilico Medicine aims to dramatically shorten this time by applying deep
learning techniques. The most important aspect of deep learning AI drug
discovery methods is the ability to design novel molecular structures with
specific characteristics of interest.
competition, participants should design and train Generative Deep Neural
Networks, conditioned on molecular fingerprints, to show the ability to
generate new molecular structures with similar fingerprints.
has been hosting hackathons since its inception, and hackathons are one of the
company's primary tools for recruiting new talent. Over the years, the company's hackathons have
attracted numerous young scientists and rising stars from around the world in
the bioscience and information industries. In April 2018, Insilico hosted a
hackathon inviting participants to develop algorithms to predict the binding
activity of ligands to proteins under specific structural conditions. Taiwanese
entrant Cynthia Yang won first place in Taiwan and second place in the world,
which led to her recruitment by Insilico Taiwan as part of its R&D staff,
where she now works on both local and international projects. The company provides an excellent working
environment, international exposure and ample opportunities for personal growth
in this fast-growing field.
We fully expect
to see some very exciting outcomes from this event, and we invite talented
young scientists in Taiwan and around the world to participate!
To register for
the MolHack 2019 Online Hackathon, please visit this link:
The Rise of Deep Learning
Over the past few
years, deep learning has become an essential research tool in many different
domains and industries. The latest advancements have made it possible for
neural networks to perform certain tasks better than humans. Deep learning
techniques have also helped us to find solutions to previously impossible
problems, and this will continue to be a trend well into the future.
With this rise in
deep learning, the share of artificial intelligence-related jobs has risen from
20% in 2016 to 31.6% in 2017 and continues to grow. It is estimated that the
number of jobs related to artificial intelligence will reach 2.3 million in
About Insilico Medicine
The expression in silico is an allusion to the commonly
used Latin phrases in biology, in vivo, in vitro and in
situ, that refer to experiments done inside living organisms, in the lab,
or where they are found in nature, respectively. In
silico refers to biological experiments that are "performed on
silicon, via computer simulation."
pioneered applications of generative adversarial networks (GANs) and
reinforcement learning for the generation of novel molecular structures for
diseases with both a known target and with no known targets. It is a pioneer in the use of deep learning to
assist the generation of novel molecular structures with desired
characteristics. Insilico Medicine is committed to using deep learning
techniques to help shorten drug development cycle time and cost and to
accelerate the research and development of anti-aging and disease-related
collaborates with pharmaceutical companies worldwide and is pursuing new drug
discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's
Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging.
The company's Smart's Pharma.AI division
is currently a collaborative research and development partner for
biotechnology, pharmaceutical, and skin care manufacturers worldwide, and
provides advanced artificial intelligence learning services to many governments
Insilico Medicine is located in the
Emerging Technology Center of the East Campus of Johns Hopkins University in
Rockville, MD USA. It has R&D resource centers in Belgium, Russia, Taiwan,
Korea, and the United Kingdom.
In 2017, Nvidia named Insilico Medicine
as one of the Top 5 AI companies for social impact potential. In 2018, CB
Insights listed the company among its global top 100 AI companies. In 2018 it
received the Frost & Sullivan 2018 North American Artificial
Intelligence for Aging Research and Drug Development Award accompanied by
an industry brief.
Artur Kadurin, CEO of Insilico Taiwan Ltd.
Consultant Co., Ltd., Shen An Chueh
+886-2-23691318#103 Mobile: +886-975-019-217